Oakworth Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Oakworth Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,491	Closed	-$825K	–	612
2021 Q2	$825K	Hold	4,491	–	–	0.08%	75
2021 Q1	$687K	Hold	4,491	–	–	0.08%	82
2020 Q4	$702K	Hold	4,491	–	–	0.09%	72
2020 Q3	$514K	Buy	4,491 +200	+5%	+$21.6K	0.08%	83
2020 Q2	$482K	Buy	4,291 +2,091	+95%	+$222K	0.09%	83
2020 Q1	$198K	Hold	2,200	–	–	0.05%	134
2019 Q4	$239K	Hold	2,200	–	–	0.04%	143
2019 Q3	$215K	Hold	2,200	–	–	0.04%	145
2019 Q2	$288K	Hold	2,200	–	–	0.05%	133
2019 Q1	$297K	Hold	2,200	–	–	0.06%	128
2018 Q4	$214K	Hold	2,200	–	–	0.05%	147
2018 Q3	$306K	Hold	2,200	–	–	0.06%	129
2018 Q2	$273K	Hold	2,200	–	–	0.06%	136
2018 Q1	$259K	Buy	2,200 +200	+10%	+$23.9K	0.06%	133
2017 Q4	$220K	Hold	2,000	–	–	0.05%	150
2017 Q3	$285K	Hold	2,000	–	–	0.07%	120
2017 Q2	$243K	Hold	2,000	–	–	0.07%	135
2017 Q1	$242K	Sell	2,000 -48	-2%	-$6.19K	0.07%	137
2016 Q4	$251K	Hold	2,048	–	–	0.08%	129
2016 Q3	$251K	Hold	2,048	–	–	0.09%	118
2016 Q2	$309K	Hold	2,048	–	–	0.12%	101
2016 Q1	$285K	Hold	2,048	–	–	0.11%	100
2015 Q4	$391K	Hold	2,048	–	–	0.16%	78
2015 Q3	$320K	Hold	2,048	–	–	0.17%	54
2015 Q2	$404K	Hold	2,048	–	–	0.19%	52
2015 Q1	$347K	Hold	2,048	–	–	0.16%	67
2014 Q4	$379K	Buy	2,048 +2,000	+4,167%	+$371K	0.2%	61
2014 Q3	$8K	Hold	48	–	–	﹤0.01%	302
2014 Q2	$8K	Hold	48	–	–	﹤0.01%	303
2014 Q1	$7K	Hold	48	–	–	﹤0.01%	309
2013 Q4	$6K	Buy	+48	New	+$5.76K	﹤0.01%	303

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Oakworth Capital's ALXN Position: Q3 2021 in Review

Oakworth Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,491 shares — an estimated $825K sold.

Oakworth Capital first reported a position in ALXN in Q4 2013 and held it in 31 quarters. The position peaked at $825K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Oakworth Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Oakworth Capital sold 4,491 Alexion Pharmaceuticals shares in Q3 2021, an estimated $825K.
Oakworth Capital first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 31 quarters.
Oakworth Capital's Alexion Pharmaceuticals position peaked at $825K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Oakworth Capital's 13F filing for Q3 2021, filed 10 Nov 2021.